X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Stroke Patients To Get A Relief With Spinal Cord Stimulation

Content Team by Content Team
24th February 2023
in Clinical Trials, Featured, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

A small clinical trial has suggested that spinal cord stimulation may help stroke patients regain movement in their limbs and hands. In an article published in Nature Medicine, researchers detailed the experience of the first two people treated in a clinical trial involving a spinal implant. The implant improved the patients’ strength, grip force, and movement, thereby enabling them to perform previously impossible actions.

Clinical proof that spinal cord stimulation- SCS can aid in the rehabilitation of leg motor function in individuals with spinal cord injuries has previously been produced by other organizations. Nevertheless, since strokes occur in the brain rather than the spine, there was some uncertainty as to whether the intervention would be effective for patients dealing with the consequences of the cerebrovascular event. The clinical trial is the first step in the process of addressing those scepticisms.

In order to boost the excitement of motoneurons in the arm and hand, researchers inserted two leads in the necks of the patients. According to a professor of mechanical engineering at Carnegie Mellon University and a co-senior author, Douglas Weber, this strategy is based on the understanding of sensory nerves in the arm and hand that communicate with motor neurons in the spinal cord, which in turn control muscles.

According to Weber in a statement, these sensory neurons can be stimulated to increase the activity of muscles that have been damaged by a stroke. The patient still has complete control over their emotions, which is important. The stimulation is supportive and only strengthens muscle activation when patients are attempting to move.

The two subjects’ grip strength dramatically increased after getting the implant. The older, more severely impaired patients saw the biggest change, with an increase of 108%. This had real-world benefits, allowing the patient to do things independently that they hadn’t been able to do in years, like open a lock or eat with a knife and fork.

According to the procedure, the leads have to be taken out after 29 days. The subjects maintained some benefits even after the implants were removed, according to later evaluations. No serious adverse events were reported.

The study does not have a control arm, so there is potential to question the impact of the implant. However, the team is encouraged enough by the early data to continue, and the researchers are still enrolling patients in the trial.

Previous Post

Major Trial Reveals Simplified HIV Treatment Options Perfect

Next Post

More Monitoring Required of Institutional Review Boards

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

More Monitoring Required of Institutional Review Boards

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In